section name header

Evidence summaries

Verapamil in Patients with Cardiovascular Disease

Verapamil use appears not to be associated with harm in patients with myocardial infarction. Level of evidence: "B"

A systematic review 1 including 66 studies was abstracted in DARE. Combined relative risk of reinfarction ranged from 0.79 to 0.80 in favour of verapamil. The range of the effect of mortality ranged from a 5.6% increase to a 18.5% reduction, the combined odds reduction favouring verapamil.

    References

    • Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998 Sep;21(9):633-41. [PubMed][DARE]

Primary/Secondary Keywords